Top 10 Pharmaceutical Stocks with Highest Upside: MRNA, BSPM, DARA, CYCC, CBP, CYTR, HEB, AVNR, XOMA, EPCT (May 09, 2011)

tdp2664
China Analyst

Below are the top 10 Pharmaceutical stocks with highest upside potential, UPDATED TODAY before 4:30 AM ET, based on the difference between current price and Wall Street analysts' average target price. One Chinese company (CBP) is on the list.

Marina Biotech, Inc. (NASDAQ:MRNA) has the 1st highest upside potential in this segment of the market. Its upside is 507.5%. Its consensus target price is $3.25 based on the average of all estimates. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) has the 2nd highest upside potential in this segment of the market. Its upside is 340.3%. Its consensus target price is $7.00 based on the average of all estimates. DARA BioSciences, Inc. (NASDAQ:DARA) has the 3rd highest upside potential in this segment of the market. Its upside is 325.6%. Its consensus target price is $11.58 based on the average of all estimates. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) has the 4th highest upside potential in this segment of the market. Its upside is 236.9%. Its consensus target price is $4.75 based on the average of all estimates. China Botanic Pharmaceutical Inc (AMEX:CBP) has the 5th highest upside potential in this segment of the market. Its upside is 227.5%. Its consensus target price is $4.88 based on the average of all estimates.

CytRx Corporation (NASDAQ:CYTR) has the 6th highest upside potential in this segment of the market. Its upside is 221.0%. Its consensus target price is $2.60 based on the average of all estimates. Hemispherx BioPharma, Inc (AMEX:HEB) has the 7th highest upside potential in this segment of the market. Its upside is 206.1%. Its consensus target price is $1.50 based on the average of all estimates. AVANIR Pharmaceuticals (NASDAQ:AVNR) has the 8th highest upside potential in this segment of the market. Its upside is 194.8%. Its consensus target price is $12.00 based on the average of all estimates. XOMA Limited (NASDAQ:XOMA) has the 9th highest upside potential in this segment of the market. Its upside is 188.5%. Its consensus target price is $8.80 based on the average of all estimates. EpiCept Corporation (NASDAQ:EPCT) has the 10th highest upside potential in this segment of the market. Its upside is 166.4%. Its consensus target price is $1.75 based on the average of all estimates.